Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic sibling cord blood cells
- Development stage
- Unknown
- Lead developer
- Murdoch Children’s Research Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic sibling cord blood cells is an investigational cell therapy consisting of fully HLA-matched umbilical cord blood (UCB) stem cells. Developed and studied by the Murdoch Children's Research Institute (MCRI) in collaboration with the Cerebral Palsy Alliance and Cell Care, this therapy is intended for the treatment of cerebral palsy (CP) in children. The cells are collected from a sibling's cord blood at birth and administered via intravenous infusion. The proposed mechanism of action is paracrine-mediated, where the cells migrate to areas of brain injury and release factors that activate endogenous repair mechanisms, reduce neuroinflammation, and promote tissue regeneration. Results from the SCUBI-CP Phase 1 clinical trial (published in 2022) indicated that the treatment is safe and feasible for pediatric patients.
- Other names
- sibling umbilical cord blood cellsHLA-matched sibling cord blood cellssibling cord blood cells
Beyond the preview
Go deeper on allogeneic sibling cord blood cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic sibling cord blood cells.